Literature DB >> 22703916

The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.

Keith Duffy1, Douglas Grossman.   

Abstract

The dysplastic nevus is a discreet histologic entity that exhibits some clinical and histologic features overlapping with common nevi and melanoma. These overlapping features present a therapeutic challenge, and with a lack of accepted guidelines, the management of dysplastic nevi remains a controversial subject. Although some differences between dysplastic and common nevi can be detected at the molecular level, there are currently no established markers to predict biologic behavior. In part II of this continuing medical education article, we will review the molecular aspects of dysplastic nevi and their therapeutic implications. Our goal is to provide the clinician with an up-to-date understanding of this entity to facilitate clinical management of patients with nevi that have histologic dysplasia.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22703916      PMCID: PMC3621132          DOI: 10.1016/j.jaad.2012.03.013

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  99 in total

Review 1.  Strategies for early melanoma detection: Approaches to the patient with nevi.

Authors:  Agnessa Gadeliya Goodson; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-05       Impact factor: 11.527

2.  Altered molecular pathways in melanocytic lesions.

Authors:  Maria Scatolini; Maurizia Mello Grand; Enrico Grosso; Tiziana Venesio; Alberto Pisacane; Antonella Balsamo; Roberta Sirovich; Mauro Risio; Giovanna Chiorino
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

3.  Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?

Authors:  Kristen Decarlo; Shi Yang; Andrew Emley; Narendra Wajapeyee; Michael Green; Meera Mahalingam
Journal:  Hum Pathol       Date:  2010-03-16       Impact factor: 3.466

4.  Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi.

Authors:  Agnessa Gadeliya Goodson; Scott R Florell; Kenneth M Boucher; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-12-16       Impact factor: 11.527

5.  Recurrent nevus phenomenon: a clinicopathologic study of 357 cases and histologic comparison with melanoma with regression.

Authors:  Roy King; Brett A Hayzen; Robert N Page; Paul B Googe; Deborah Zeagler; Martin C Mihm
Journal:  Mod Pathol       Date:  2009-03-06       Impact factor: 7.842

6.  Dysplastic nevus syndrome with development of multiple melanomas. A surgical concept for prophylaxis.

Authors:  Corinna Brod; Wilfried Schippert; Helmut Breuninger
Journal:  J Dtsch Dermatol Ges       Date:  2009-09       Impact factor: 5.584

7.  Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi.

Authors:  Pedram Gerami; Amanda Wass; Mariam Mafee; Yuaquin Fang; Melissa P Pulitzer; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

8.  Role for IGFBP7 in senescence induction by BRAF.

Authors:  Narendra Wajapeyee; Ryan W Serra; Xiaochun Zhu; Meera Mahalingam; Michael R Green
Journal:  Cell       Date:  2010-05-28       Impact factor: 41.582

9.  BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.

Authors:  L P Nguyen; A Emley; N Wajapeyee; M R Green; M Mahalingam
Journal:  Br J Dermatol       Date:  2009-11-16       Impact factor: 9.302

10.  Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi.

Authors:  Mario Falchi; Veronique Bataille; Nicholas K Hayward; David L Duffy; Julia A Newton Bishop; Tomi Pastinen; Alessandra Cervino; Zhen Z Zhao; Panos Deloukas; Nicole Soranzo; David E Elder; Jennifer H Barrett; Nicholas G Martin; D Timothy Bishop; Grant W Montgomery; Timothy D Spector
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

View more
  13 in total

1.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

2.  Expression of Bcl-2, Melan A and HMB-45 in Dysplastic Nevi.

Authors:  Oana Maria Patrascu; Mariana Costache; Adrian Vasile Dumitru; Corina Nicoleta Mehotin; Maria Sajin; Anca Mihaela Lazaroiu
Journal:  Maedica (Bucur)       Date:  2016-03

Review 3.  [Dysplastic melanocytic nevus].

Authors:  E Bierhoff
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

Review 4.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

Review 5.  Nanoparticle-Based Combination Therapy for Melanoma.

Authors:  Hongbo Chen; Kai Hou; Jing Yu; Le Wang; Xue Chen
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

6.  The so-called dysplastic nevus is not dysplastic at all.

Authors:  Raman Madan; Sheng Chen
Journal:  Dermatol Pract Concept       Date:  2013-01-31

7.  Novel multiple markers to distinguish melanoma from dysplastic nevi.

Authors:  Guohong Zhang; Gang Li
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

8.  A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma.

Authors:  Madhuri Bhandaru; Gholamreza Safaee Ardekani; Guohong Zhang; Magdalena Martinka; Kevin J McElwee; Gang Li; Anand Rotte
Journal:  BMC Cancer       Date:  2014-06-03       Impact factor: 4.430

9.  Colorectal Cancer with Residual Polyp of Origin: A Model of Malignant Transformation.

Authors:  Brooke R Druliner; Shahrooz Rashtak; Xiaoyang Ruan; Taejeong Bae; Nikolaos Vasmatzis; Daniel O'Brien; Ruth Johnson; Donna Felmlee-Devine; Jill Washechek-Aletto; Nivedita Basu; Hongfang Liu; Thomas Smyrk; Alexej Abyzov; Lisa A Boardman
Journal:  Transl Oncol       Date:  2016-07-09       Impact factor: 4.243

10.  In vivo assessment of optical properties of melanocytic skin lesions and differentiation of melanoma from non-malignant lesions by high-definition optical coherence tomography.

Authors:  M A L M Boone; M Suppa; F Dhaenens; M Miyamoto; A Marneffe; G B E Jemec; V Del Marmol; R Nebosis
Journal:  Arch Dermatol Res       Date:  2015-11-13       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.